Involvement of spinal lipoxygenase metabolites in hyperalgesia and opioid tolerance

European Journal of Pharmacology

Volumn 491, Issue 1, 2004, Pages 21-30

  Trang, Tuan ^a   McNaull, Benjamin ^a   Quirion, Remi ^b   Jhamandas, Khem ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Hyperalgesia; Lipoxygenase; Opioid tolerance; Spinal, rat

Indexed keywords

15 HYDROXYPEROXYEICOSATETRANOIC ACID; 2 (2,6 DIHYDROXYHEXYL) 6 (3 HYDROXY 1,5 UNDECADIENYL)PYRIDINE; FORMALDEHYDE; ICOSATETRAENOIC ACID; LEUKOTRIENE RECEPTOR STIMULATING AGENT; LIPOXYGENASE; MORPHINE; OPIATE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; DRUG POTENCY; HYPERALGESIA; MALE; METABOLITE; MORPHINE TOLERANCE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST; THERMAL STIMULATION;

ANALGESICS, OPIOID; ANIMALS; BENZOQUINONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FLAVANONES; FORMALDEHYDE; HINDLIMB; HYPERALGESIA; INJECTIONS, SPINAL; LEUKOTRIENE B4; LEUKOTRIENES; LIPID PEROXIDES; LIPOXYGENASE; LIPOXYGENASE INHIBITORS; MALE; MORPHINE; NORDIHYDROGUAIARETIC ACID; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; TIME FACTORS;

EID: 16544394765     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.03.022     Document Type: Article

References (70)

1. Abbott F.V., Franklin K.B., Ludwick R.J., Melzack R. Apparent lack of tolerance in the formalin test suggests different mechanisms for morphine analgesia in different types of pain. Pharmacol. Biochem. Behav. 15:1981;637-640.
2. Ashida Y., Saijo T., Kuriki H., Makino H., Terao S., Maki Y. Pharmacological profile of AA-861, a 5-lipoxygenase inhibitor. Prostaglandins. 26:1983;955-972.
3. Bisgaard H., Kristensen J.K. Leukotriene B4 produces hyperalgesia in humans. Prostaglandins. 30:1985;791-797.
4. Capasso A. Further studies on the involvement of the arachidonic acid cascade in the acute dependence produced by mu, kappa and delta opioid agonists in isolated tissues. Neuropharmacology. 38:1999;871-877.
5. Christie M.J., Connor M., Vaughan C.W., Ingram S.L., Bagley E.E. Cellular actions of opioids and other analgesics: implications for synergism in pain relief. Clin. Exp. Pharmacol. Physiol. 27:2000;520-523.
6. Crain S.M., Shen K.F. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res. 888:2001;75-82.
7. Dailey L.A., Imming P. 12-Lipoxygenase: classification, possible therapeutic benefits from inhibition, and inhibitors. Curr. Med. Chem. 6:1999;389-398.
8. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
9. Dickenson A.H., Sullivan A.F. Peripheral origins and central modulation of subcutaneous formalin-induced activity of rat dorsal horn neurones. Neurosci. Lett. 83:1987;207-211.
10. Dubuisson D., Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 4:1977;161-174.
11. Dunbar S.A., Karamov I.G., Buerkle H. The effect of spinal ibuprofen on opioid withdrawal in the rat. Anesth. Analg. 91:2000;417-422.
12. Ford-Hutchinson A.W., Bray M.A., Smith M.J. Lipoxygenase products and the polymorphonuclear leucocyte. Agents Actions. 10:1980;548-550.
13. Gilbert A., Le Gouill C., Thompson C., Pasternak G., Stankova J., Rola-Pleszczynski M. Expression and modulation of the cysteinyl leukotriene receptor 1 (cyslt1r) in the central nervous system. Soc. Neurosci. Abstr. 2003;695.11.
14. Gilroy D.W., Tomlinson A., Willoughby D.A. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur. J. Pharmacol. 355:1998;211-217.
15. Gök S., Onal A., Cinar M.G., Evinc A. The antinociceptive effect of leukotriene D(4) receptor antagonist, MK-571, in mice: possible involvement of opioidergic mechanism. Eur. J. Pharmacol. 386:1999;195-200.
16. Gouarderes C., Sutak M., Zajac J.M., Jhamandas K. Role of adenosine in the spinal antinociceptive and morphine modulatory actions of neuropeptide FF analogs. Eur. J. Pharmacol. 406:2000;391-401.
17. Hope W.C., Welton A.F., Fiedler-Nagy C., Batula-Bernardo C., Coffey J.W. In vitro inhibition of the biosynthesis of slow reacting substance of anaphylaxis (SRS-A) and lipoxygenase activity by quercetin. Biochem. Pharmacol. 32:1983;367-371.
18. Hua X.Y., Chen P., Marsala M., Yaksh T.L. Intrathecal substance P-induced thermal hyperalgesia and spinal release of prostaglandin E2 and amino acids. Neuroscience. 89:1999;525-534.
19. Hwang S.W., Cho H., Kwak J., Lee S.Y., Kang C.J., Jung J., Cho S., Min K.H., Suh Y.G., Kim D., Oh U. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6155-6160.
20. Jain N.K., Kulkarni S.K., Singh A. Role of cysteinyl leukotrienes in nociceptive and inflammatory conditions in experimental animals. Eur. J. Pharmacol. 423(1):2001;85-92.
21. Jhamandas K., Yaksh T.L., Harty G., Szolcsanyi J., Go V.L. Action of intrathecal capsaicin and its structural analogues on the content and release of spinal substance P: selectivity of action and relationship to analgesia. Brain Res. 306:1984;215-225.
22. Kawajiri H., Zhuang D., Qiao N., Yoshimoto T., Yamamoto M., Iseki S., Hamaguchi K. Expression of arachidonate 12-lipoxygenase in rat tissues: a possible role in glucagon secretion. J. Histochem. Cytochem. 48:2000;1411-1419.
23. Kirchner T., Aparicio B., Argentieri D.C., Lau C.Y., Ritchie D.M. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot. Essent. Fat. Acids. 56:1997;417-423.
24. Levine J.D., Lau W., Kwiat G., Goetzl E.J. Leukotriene B4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science. 225:1984;743-745.
25. Levine J.D., Gooding J., Donatoni P., Borden L., Goetzl E.J. The role of the polymorphonuclear leukocyte in hyperalgesia. J. Neurosci. 5:1985;3025-3029.
26. Levine J.D., Lam D., Taiwo Y.O., Donatoni P., Goetzl E.J. Hyperalgesic properties of 15-lipoxygenase products of arachidonic acid. Proc. Natl. Acad. Sci. U. S. A. 83:1986;5331-5334.
27. Loomis C.W., Cervenko F.W., Jhamandas K., Sutak M., Milne B. Analgesia and autonomic function following intrathecal administration of morphine and norepinephrine to the rat. Can. J. Physiol. Pharmacol. 63:1985;656-662.
28. Loomis C.W., Milne B., Cervenko F.W. Determination of cross tolerance in rat spinal cord using intrathecal infusion via sequential mini-osmotic pumps. Pharmacol. Biochem. Behav. 26:1987;131-139.
29. Malmberg A.B., Yaksh T.L. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science. 257:1992;1276-1279.
30. Malmberg A.B., Yaksh T.L. Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain. 54:1993;291-300.
31. Mantyh P.W., Rogers S.D., Honore P., Allen B.J., Ghilardi J.R., Li J., Daughters R.S., Lappi D.A., Wiley R.G., Simone D.A. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science. 278:1997;275-279.
32. Mao J., Price D.D., Mayer D.J. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J. Neurosci. 14:1994;2301-2312.
33. Mao J., Price D.D., Lu J., Mayer D.J. Antinociceptive tolerance to the mu-opioid agonist DAMGO is dose-dependently reduced by MK-801 in rats. Neurosci. Lett. 250:1998;193-196.
34. Marriott D., Wilkin G.P., Coote P.R., Wood J.N. Eicosanoid synthesis by spinal cord astrocytes is evoked by substance P; possible implications for nociception and pain. Adv. Prostaglandin Thromboxane Leukotriene Res. 21B:1991;739-741.
35. Marriott D.R., Wilkin G.P., Wood J.N. Substance P-induced release of prostaglandins from astrocytes: regional specialisation and correlation with phosphoinositol metabolism. J. Neurochem. 56:1991;259-265.
36. Martin H.A., Basbaum A.I., Kwiat G.C., Goetzl E.J., Levine J.D. Leukotriene and prostaglandin sensitization of cutaneous high-threshold C- and A-delta mechanonociceptors in the hairy skin of rat hindlimbs. Neuroscience. 22:1987;651-659.
37. Martin H.A., Basbaum A.I., Goetzl E.J., Levine J.D. Leukotriene B4 decreases the mechanical and thermal thresholds of C-fiber nociceptors in the hairy skin of the rat. J. Neurophysiol. 60:1988;438-445.
38. Minami T., Uda R., Horiguchi S., Ito S., Hyodo M., Hayaishi O. Allodynia evoked by intrathecal administration of prostaglandin E2 to conscious mice. Pain. 57:1994;217-223.
39. Owen J.A., Milne B., Jhamandas K., Nakatsu K. Assembly of an inexpensive tail flick analgesia meter. J. Pharmacol. Methods. 6:1981;33-37.
40. Patel H.H., Fryer R.M., Gross E.R., Bundey R.A., Hsu A.K., Isbell M., Eusebi L.O., Jensen R.V., Gullans S.R., Insel P.A., Nithipatikom K., Gross G.J. 12-Lipoxygenase in opioid-induced delayed cardioprotection: gene array, mass spectrometric, and pharmacological analyses. Circ. Res. 92:2003;676-682.
41. Porro C.A., Cavazzuti M. Spatial and temporal aspects of spinal cord and brainstem activation in the formalin pain model. Prog. Neurobiol. 41:1993;565-607.
42. Powell K.J., Hosokawa A., Bell A., Sutak M., Milne B., Quirion R., Jhamandas K. Comparative effects of cyclo-oxygenase and nitric oxide synthase inhibition on the development and reversal of spinal opioid tolerance. Br. J. Pharmacol. 127:1999;631-644.
43. Powell K.J., Ma W., Sutak M., Doods H., Quirion R., Jhamandas K. Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists. Br. J. Pharmacol. 131:2000;875-884.
44. Powell K.J., Quirion R., Jhamandas K. Inhibition of neurokinin-1- substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. Eur. J. Neurosci. 18:2003;1572-1583.
45. Rackham A., Ford-Hutchinson A.W. Inflammation and pain sensitivity: effects of leukotrienes D4, B4 and prostaglandin E1 in the rat paw. Prostaglandins. 25:1983;193-203.
46. Ritchie J., Pitcher G.M., Sharif R.N. Lipoxygenase inhibition depresses hyperalgesia induced by intrathecal administration of substance P, NMDA and AMPA in the rat. Soc. Neurosci. Abstr. 26:2000;1958.
47. Salari H., Braquet P., Borgeat P. Comparative effects of indomethacin, acetylenic acids, 15-HETE, nordihydroguaiaretic acid and BW755C on the metabolism of arachidonic acid in human leukocytes and platelets. Prostaglandins Leukot. Med. 13:1984;53-60.
48. Sekiya K., Okuda H. Selective inhibition of platelet lipoxygenase by baicalein. Biochem. Biophys. Res. Commun. 105:1982;1090-1095.
49. Serhan C.N., Hamberg M., Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. U. S. A. 1984:1984;5335-5339.
50. Serhan C.N., Hamberg M., Samuelsson B. Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem. Biophys. Res. Commun. 118(3):1984;943-949.
51. Shen K.F., Crain S.M. Cholera toxin-B subunit blocks excitatory opioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesia and attenuating opioid tolerance/dependence. Brain Res. 919:2001;20-30.
52. Shin J., Cho H., Hwang S.W., Jung J., Shin C.Y., Lee S.Y., Kim S.H., Lee M.G., Choi Y.H., Kim J., Haber N.A., Reichling D.B., Khasar S., Levine J.D., Oh U. Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc. Natl. Acad. Sci. U. S. A. 99:2002;10150-10155.
53. Skofitsch G., Jacobowitz D.M. Calcitonin gene-related peptide coexists with substance P in capsaicin sensitive neurons and sensory ganglia of the rat. Peptides. 6:1985;747-754.
54. Smullin D.H., Skilling S.R., Larson A.A. Interactions between substance P, calcitonin gene-related peptide, taurine and excitatory amino acids in the spinal cord. Pain. 42:1990;93-101.
55. Sugimoto M., Kuraishi Y., Satoh M., Takagi H. Involvement of medullary opioid-peptidergic and spinal noradrenergic systems in the regulation of formalin-induced persistent pain. Neuropharmacology. 25:1986;481-485.
56. Taiwo Y.O., Levine J.D. Characterization of the arachidonic acid metabolites mediating bradykinin and noradrenaline hyperalgesia. Brain Res. 458:1988;402-406.
57. Tjolsen A., Berge O.G., Hunskaar S., Rosland J.H., Hole K. The formalin test: an evaluation of the method. Pain. 51:1992;5-17.
58. Tominaga M., Caterina M.J., Malmberg A.B., Rosen T.A., Gilbert H., Skinner K., Raumann B.E., Basbaum A.I., Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 21:1998;531-543.
59. Tonussi C.R., Ferreira S.H. Tumour necrosis factor-alpha mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain. 82:1999;81-87.
60. Trang T., Sutak M., Quirion R., Jhamandas K. The role of spinal neuropeptides and prostaglandins in opioid physical dependence. Br. J. Pharmacol. 136:2002;37-48.
61. Trang T., Sutak M., Quirion R., Jhamandas K. Spinal administration of lipoxygenase inhibitors suppresses behavioural and neurochemical manifestations of nalipoxygenaseone-precipitated opioid withdrawal. Br. J. Pharmacol. 140:2003;295-304.
62. Uda R., Horiguchi S., Ito S., Hyodo M., Hayaishi O. Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice. Brain Res. 510:1990;26-32.
63. Valtschanoff J.G., Rustioni A., Guo A., Hwang S.J. Vanilloid receptor VR1 is both presynaptic and postsynaptic in the superficial laminae of the rat dorsal horn. J. Comp Neurol. 436:2001;225-235.
64. Vasko M.R., Campbell W.B., Waite K.J. Prostaglandin E2 enhances bradykinin-stimulated release of neuropeptides from rat sensory neurons in culture. J. Neurosci. 14:1994;4987-4997.
65. Vaughan C.W., Ingram S.L., Connor M.A., Christie M.J. How opioids inhibit GABA-mediated neurotransmission. Nature. 390:1997;611-614.
66. Wong C.S., Hsu M.M., Chou R., Chou Y.Y., Tung C.S. Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats. Br. J. Anaesth. 85:2000;747-751.
67. Yaksh T.L., Rudy T.A. Analgesia mediated by a direct spinal action of narcotics. Science. 192:1976;1357-1358.
68. Yaksh T.L., Malmberg A.B. Spinal actions of NSAIDS in blocking spinally mediated hyperalgesia: the role of cyclooxygenase products. Agents Actions. Suppl. 41:1993;89-100.
69. Yoshimoto T., Yokoyama C., Ochi K., Yamamoto S., Maki Y., Ashida Y., Terao S., Shiraishi M. 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4- benzoquinone (AA-861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochim. Biophys. Acta. 713(2):1982;470-473.
70. Zhang R.X., Mi Z.P., Qiao J.T. Changes of spinal substance P, calcitonin gene-related peptide, somatostatin, Met-enkephalin and neurotensin in rats in response to formalin-induced pain. Regul. Pept. 51:1994;25-32.